What is the NVIVG in short and what does your organisation stand for?
The Dutch Society of Internists Vascular Medicine (NVIVG) is the official scientific society of internists vascular medicine. The NVIVG consists of 170 active members including prominent nationally and internationally renowned researchers in the field of cardiovascular disease including several members involved in national and European cardiovascular guidelines.
What does NVIVG hope to get out of the partnership with the DCVA?
The aims of the NVIVG include the improvement of healthcare of patients with established cardiovascular disease (CVD) and/or high risk of CVD in the Netherlands. Our emphasis is to improve quality of care within the domain of Internal Medicine (in collaboration with the Dutch Society of Internal Medicine (NIV)) with a focus on vascular medicine. The NVIVG collaborates with other healthcare providers including General Practitioners involved in vascular healthcare in the Netherlands. Furthermore our aim is to develop and disseminate knowledge concerning vascular medicine to internist vascular medicine (in training) as well as other relevant healthcare providers by providing educational activities such as courses and symposia. Lastly we represent the interests of internists vascular medicine in the Netherlands.
What does NVIVG add to the DCVA, why should we be happy that NVIVG is participating?
We believe we can contribute to the aims of the DCVA as vascular internists by our broad perspective on CVD and our strong focus on prevention. Vascular medicine specialists are in the forefront when it comes to lipid management, blood pressure treatment, diabetes treatment especially in the setting of preexisting cardiovascular disease and venous thromboembolism. Due to us being internists there is always as strong link to the subject of multimorbidity.
Why is it good to be part of the DCVA?
For the NVIVG membership of the DCVA brings us closer to our colleagues with whom we improve the care for our everyday patients and collaborate in the scientific development of new strategies to further decrease the risk of (recurrent) cardiovascular disease.